INVESTMENTS

Biotech firm Kailos Genetics gets backing from IC venture arm In-Q-Tel

Biotechnology firm Kailos Genetics has received an investment from the intelligence community investment arm In-Q-Tel to help further develop a new genetic sequencing laboratory.

Terms of the partnership were not disclosed. IQT seeks to further spur efforts on both the laboratory and cloud-based software used to perform genetic sequencing.

Huntsville, Ala.-based Kailos started in 2010 to advance genetic testing for partners such as hospitals, physicians, laboratories and pharmacies. Kailos' portfolio includes a laboratory information system built to manage samples in a lab environment, perform analytics and give users reports.

Founded in 1999, IQT seeks to identify startup companies whose technologies have potential use in the intelligence community.

About the Author

Ross Wilkers is a senior staff writer for Washington Technology. He can be reached at rwilkers@washingtontechnology.com. Follow him on Twitter: @rosswilkers. Also find and connect with him on LinkedIn.

Reader Comments

Please post your comments here. Comments are moderated, so they may not appear immediately after submitting. We will not post comments that we consider abusive or off-topic.

Please type the letters/numbers you see above

What is your e-mail address?

My e-mail address is:

Do you have a password?

Forgot your password? Click here
close

Trending

  • Dive into our Contract Award database

    In an exclusive for WT Insider members, we are collecting all of the contract awards we cover into a database that you can sort by contractor, agency, value and other parameters. You can also download it into a spreadsheet. Our databases track awards back to 2013. Read More

  • Navigating the trends and issues of 2016 Nick Wakeman

    In our latest WT Insider Report, we pull together our best advice, insights and reporting on the trends and issues that will shape the market in 2016 and beyond. Read More

contracts DB

Washington Technology Daily

Sign up for our newsletter.

I agree to this site's Privacy Policy.